Background: Data concerning long-term mortality predictors among large, purely diabetic hemodialysis collectives are scarce. Methods: We used data from a multicenter, prospective, randomized trial among 1,255 hemodialysis patients with type 2 diabetes mellitus (T2DM) and its observational follow-up study. The association of 10 baseline candidate variables with mortality was assessed by Cox proportional hazards regression. Results: Overall, 103 participants survived the median follow-up of 11.5 years. Significant predictors of mortality were age (hazard ratio [HR] 1.03, 95% CI 1.02–1.04), cardiovascular (HR 1.42, 95% CI 1.25–1.62) and peripheral vascular disease (HR 1.55, 95% CI 1.36–1.76), higher hemoglobin A1c (HbA1c; HR 1.08, 95% CI 1.03–1.14), and loss of self-dependency (HR 1.20, 95% CI 1.03–1.39). Higher albumin (HR 0.72, 95% CI 0.59–0.89) and body mass index (BMI; HR 0.98, 95% CI 0.96–0.99) had protective associations. There was no significant association with sex, diabetes duration, and cerebrovascular diseases. Subgroup analyses by age and diabetes duration showed stronger associations of cardiovascular disease, HbA1c, albumin, BMI, and loss of self-dependency in younger patients and/or shorter diabetes duration. Loss of self-dependency and energy resources (albumin, BMI) increased mortality more severely in women, whilst the impact of cardiovascular and peripheral vascular diseases was more pronounced in men. Conclusion: Long-term mortality risk in patients with T2DM on hemodialysis was associated with higher age, vascular diseases, HbA1c, loss of self-dependency, and low energy resources. Interestingly, it does not vary between sexes. Further individualized prognosis estimation and therapy should strongly depend on age, diabetes duration, and gender.

Keywords:
Diabetic nephropathy, Long-term mortality, Predictors, Dialysis, Diabetes, 4D study, Survival
1.
Liyanage T, et al: Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015; 385: 1975–1982.
2.
ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2013. Academic Medical Center, Department of Medical Informatics, Amsterdam, 2015.
3.
Chatterjee S, Khunti K, Davies MJ: Type 2 diabetes. Lancet 2017; 389: 2239–2251.
4.
van Diepen M, et al: Predicting mortality in patients with diabetes starting dialysis. PLoS One 2014; 9:e89744.
5.
Freedman BI, et al: Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 2011; 6: 1635–1643.
6.
Segall L, et al: Protein-energy wasting, as well as overweight and obesity, is a long-term risk factor for mortality in chronic hemodialysis patients. Int Urol Nephrol 2014; 46: 615–621.
7.
Wanner C, et al: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238–248.
8.
Wanner C, et al: Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res 2004; 27: 259–266.
9.
Krane V, et al: Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int 2016; 89(6):1380–1387.
10.
Jassal SV, Douglas JF, Stout RW: Prognostic markers in older patients starting renal replacement therapy. Nephrol Dial Transplant 1996; 11: 1052–1057.
11.
Ifudu O, et al: Predictive value of functional status for mortality in patients on maintenance hemodialysis. Am J Nephrol 1998; 18(2):109–116.
12.
Catalano C, Postorino M, Marino C: The impact of diabetes on patientss’ survival in dialysis patients with non-diabetic ­renal disease and in patients who develop diabetes during chronic dialysis. Nephrol Dial Transplant 1996; 11: 1124–1128.
13.
Noordzij M, et al: When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant 2013; 28: 2670–2677.
14.
Villar E, Chang SH, McDonald SP: Incidences, treatments, outcomes, and sex effect on survival in patients with end-stage renal disease by diabetes status in Australia and New Zealand (1991 2005). Diabetes Care 2007; 30: 3070–3076.
15.
Hecking M, et al: Sex-specific differences in hemodialysis prevalence and practices and the male-to-female mortality rate: the Dialysis Outcomes and Practice Patterns Study (DOPPS). PLoS Med 2014; 11: e1001750.
16.
Carrero JJ, et al: Sex differences in the impact of diabetes on mortality in chronic dialysis patients. Nephrol Dial Transplant 2011; 26: 270–276.
17.
de Mutsert R, et al: Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant 2008; 23:2957–2964.
18.
Orimoto Y, et al: The prognosis of patients on hemodialysis with foot lesions. J Vasc Surg 2013; 58: 1291–1299.
19.
Schiller A, et al: Vitamin D deficiency – prognostic marker or mortality risk factor in end stage renal disease patients with diabetes ­mellitus treated with hemodialysis – a prospective multicenter study. PLoS One 2015; 10: e0126586.
20.
Rajagopalan S, et al: Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Circulation 2006; 114: 1914–1922.
21.
Al-Thani H, et al: Implications of foot ulceration in hemodialysis patients: a 5-year observational study. J Diabetes Res 2014; 2014: 945075.
22.
Otani Y, et al: Effects of the ankle-brachial blood pressure index and skin perfusion pressure on mortality in hemodialysis patients. Intern Med 2013; 52: 2417–2421.
23.
Wetmore JB, et al: Relationship between stroke and mortality in dialysis patients. Clin J Am Soc Nephrol 2015; 10: 80–89.
24.
Williams ME, et al: Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival. Kidney Int 2006; 70: 1503–1509.
25.
Park JI, et al: Glycemic control and mortality in diabetic patients undergoing dialysis focusing on the effects of age and dialysis type: a prospective cohort study in Korea. PLoS One 2015; 10:e0136085.
26.
Li X, et al: HbA1c and survival in maintenance hemodialysis patients with diabetes in Han Chinese population. Int Urol Nephrol 2014; 46: 2207–2214.
27.
Ishimura E, et al: Glycemic control and ­survival of diabetic hemodialysis patients – importance of lower hemoglobin A1C levels. Diabetes Res Clin Pract 2009; 83: 320–326.
28.
Peng F, et al: The effect of glycated ­hemoglobin and albumin-corrected glycated ­serum protein on mortality in diabetic patients receiving continuous peritoneal ­dialysis. Perit Dial Int 2015; 35: 566–575.
29.
Hill CJ, et al: Glycated hemoglobin and risk of death in diabetic patients treated with hemodialysis: a meta-analysis. Am J Kidney Dis 2014; 63: 84–94.
30.
Williams ME, et al: Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses. Clin J Am Soc Nephrol 2010; 5: 1595–1601.
31.
Adler A, et al: Association between glycemia and mortality in diabetic individuals on renal replacement therapy in the U.K. Diabetes Care 2014; 37: 1304–1311.
32.
Kalantar-Zadeh K, et al: A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2001; 38: 1251–1263.
33.
Ladhani M, et al: Obesity and the risk of cardiovascular and all-cause mortality in chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant 2017; 32: 439–449.
34.
Oga EA, Eseyin OR: The obesity paradox and heart failure: a systematic review of a decade of evidence. J Obes 2016; 2016: 9040248.
35.
Rhee CM, Ahmadi SF, Kalantar-Zadeh K: The dual roles of obesity in chronic kidney disease: a review of the current literature. Curr Opin Nephrol Hypertens 2016; 25: 208–216.
36.
Deger SM, et al: Obesity, diabetes and survival in maintenance hemodialysis patients. Ren Fail 2014; 36: 546–551.
37.
Herselman M, et al: Relationship between serum protein and mortality in adults on long-term hemodialysis: exhaustive review and meta-analysis. Nutrition 2010; 26: 10–32.
38.
Vashistha T, et al: Effect of age and dialysis vintage on obesity paradox in long-term hemodialysis patients. Am J Kidney Dis 2014; 63: 612–622.
39.
United States Renal Data System: Annual Data Report, Volume 2 – ESRD in the United States, 2016, p 291.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.